The COVID-19, tuberculosis and HIV/AIDS : Ménage à Trois
Copyright © 2023 Udoakang, Djomkam Zune, Tapela, Nganyewo, Olisaka, Anyigba, Tawiah-Eshun, Owusu, Paemka, Awandare and Quashie..
In December 2019, a novel pneumonic condition, Coronavirus disease 2019 (COVID- 19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), broke out in China and spread globally. The presentation of COVID-19 is more severe in persons with underlying medical conditions such as Tuberculosis (TB), Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) and other pneumonic conditions. All three diseases are of global concern and can significantly affect the lungs with characteristic cytokine storm, immunosuppression, and respiratory failure. Co-infections of SARS-CoV-2 with HIV and Mycobacterium tuberculosis (Mtb) have been reported, which may influence their pathogenesis and disease progression. Pulmonary TB and HIV/AIDS patients could be more susceptible to SARS-CoV-2 infection leading to lethal synergy and disease severity. Therefore, the biological and epidemiological interactions of COVID-19, HIV/AIDS, and TB need to be understood holistically. While data is needed to predict the impact of the COVID-19 pandemic on these existing diseases, it is necessary to review the implications of the evolving COVID-19 management on HIV/AIDS and TB control, including therapy and funding. Also, the impact of long COVID on patients, who may have this co-infection. Thus, this review highlights the implications of COVID-19, HIV/AIDS, and TB co-infection compares disease mechanisms, addresses growing concerns, and suggests a direction for improved diagnosis and general management.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 14(2023) vom: 07., Seite 1104828 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Udoakang, Aniefiok John [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 14.02.2023 Date Revised 31.08.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fimmu.2023.1104828 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352862777 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352862777 | ||
| 003 | DE-627 | ||
| 005 | 20231226205948.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2023.1104828 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1176.xml |
| 035 | |a (DE-627)NLM352862777 | ||
| 035 | |a (NLM)36776887 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Udoakang, Aniefiok John |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The COVID-19, tuberculosis and HIV/AIDS |b Ménage à Trois |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2023 | ||
| 500 | |a Date Revised 31.08.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Udoakang, Djomkam Zune, Tapela, Nganyewo, Olisaka, Anyigba, Tawiah-Eshun, Owusu, Paemka, Awandare and Quashie. | ||
| 520 | |a In December 2019, a novel pneumonic condition, Coronavirus disease 2019 (COVID- 19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), broke out in China and spread globally. The presentation of COVID-19 is more severe in persons with underlying medical conditions such as Tuberculosis (TB), Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) and other pneumonic conditions. All three diseases are of global concern and can significantly affect the lungs with characteristic cytokine storm, immunosuppression, and respiratory failure. Co-infections of SARS-CoV-2 with HIV and Mycobacterium tuberculosis (Mtb) have been reported, which may influence their pathogenesis and disease progression. Pulmonary TB and HIV/AIDS patients could be more susceptible to SARS-CoV-2 infection leading to lethal synergy and disease severity. Therefore, the biological and epidemiological interactions of COVID-19, HIV/AIDS, and TB need to be understood holistically. While data is needed to predict the impact of the COVID-19 pandemic on these existing diseases, it is necessary to review the implications of the evolving COVID-19 management on HIV/AIDS and TB control, including therapy and funding. Also, the impact of long COVID on patients, who may have this co-infection. Thus, this review highlights the implications of COVID-19, HIV/AIDS, and TB co-infection compares disease mechanisms, addresses growing concerns, and suggests a direction for improved diagnosis and general management | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a HIV/AIDS | |
| 650 | 4 | |a co-infection | |
| 650 | 4 | |a immunosuppression | |
| 650 | 4 | |a pandemic | |
| 650 | 4 | |a susceptibility | |
| 650 | 4 | |a tuberculosis | |
| 700 | 1 | |a Djomkam Zune, Alexandra Lindsey |e verfasserin |4 aut | |
| 700 | 1 | |a Tapela, Kesego |e verfasserin |4 aut | |
| 700 | 1 | |a Nganyewo, Nora Nghochuzie |e verfasserin |4 aut | |
| 700 | 1 | |a Olisaka, Frances Ngozi |e verfasserin |4 aut | |
| 700 | 1 | |a Anyigba, Claudia Adzo |e verfasserin |4 aut | |
| 700 | 1 | |a Tawiah-Eshun, Sylvia |e verfasserin |4 aut | |
| 700 | 1 | |a Owusu, Irene Amoakoh |e verfasserin |4 aut | |
| 700 | 1 | |a Paemka, Lily |e verfasserin |4 aut | |
| 700 | 1 | |a Awandare, Gordon A |e verfasserin |4 aut | |
| 700 | 1 | |a Quashie, Peter Kojo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 14(2023) vom: 07., Seite 1104828 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g day:07 |g pages:1104828 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2023.1104828 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |b 07 |h 1104828 | ||